
Anavex Life Sciences fell 79.3% from $3.58 to $0.74, behind the S&P 500's +10.0%. Its worst day was Mar 25 (−34.6%), and its low came Nov 17 at $0.74.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.11 beat the $-0.14 estimate on $0.00 revenue.
+12.3% · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
Anavex Life Sciences shares rose 19.3%, while the S&P 500 rose 0.1%.
+19.3%, the year's best day · S&P 500 +0.1%
Anavex Life Sciences closed at its highest level of the year, 48.0% above where the year started.
+5.4% · S&P 500 +1.2%
EPS of $-0.06 beat the $-0.11 estimate on $0.00 revenue.
+6.1% · S&P 500 +0.5%
Anavex Life Sciences shares fell 34.6%, while the S&P 500 rose 0.6%.
−34.6%, the year's worst day, on 14M shares, the year's heaviest volume · S&P 500 +0.6%
EPS of $-0.06 beat the $-0.07 estimate on $0.00 revenue.
+8.4% · S&P 500 +1.7%
EPS of $0.08 beat the $-0.08 estimate on $0.00 revenue.
+14.5% · S&P 500 +0.3%
Anavex Life Sciences shares fell 14.4%, while the S&P 500 fell 0.2%.
−14.4% · S&P 500 −0.2%
Where it ended: a close of $0.74 on Nov 17, 2026. Up next: Q4 2026 earnings on Dec 1, 2026 (EPS est. $-0.11).
Nothing in the past 12 months.
All AVXL dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AVXL and SPY from Benzinga historical bars. Not investment advice.